News | December 10, 2025
Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Angelini Ventures has already invested €125 million in 22 startups
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
GV20 received an upfront payment and is eligible for additional milestone payments
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Subscribe To Our Newsletter & Stay Updated
